Lexicon reports Q4 net loss $33.8M; pilavapadin 10mg advances to Phase 3

LEXICON PHARMACEUTICALS, INC.

Q4 net loss $33.8M ($0.09/shr) vs $49.8M loss in Q4 2023; revenue $26.6M including $25M Viatris upfront.
Phase 2b PROGRESS study of pilavapadin met objectives; 10mg dose showed meaningful pain reduction vs placebo; Phase 3 targeting 2025.
Cash and investments $238.0M at Dec 31, 2024, up from $170.0M year-end 2023; full-year net loss $200.4M.
Company ceased active INPEFA promotion and discontinued Zynquista launch prep after FDA CRL; leaner R&D-focused organization.
LX9851 IND on track for 2025; sotagliflozin Phase 3 SONATA HCM trial enrolling with 500-patient target.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.